Navigation Links
National Stem Cell Holding, Inc. to Present Keynote Address at The Stem Cell Partnering Series Inaugural Meeting in San Diego
Date:2/26/2008

Tuesday February 26, 2008 9:15 am ET

MOUNTAINSIDE, N.J., Feb. 26 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (Pink Sheets: NHGI) today announced that its President Michael Cohen will present a Keynote Address, "A New Collaboration Model for Government Agencies, Academic Institutions and Development Stage Biotech Companies," at the Inaugural meeting of The Stem Cell Partnering Series: Fostering Business Collaborations & Careers in Stem Cell Science, February 28- 29, 2008, to be held at the University of California San Diego.

National Stem Cell President, Michael Cohen, stated, "I am pleased to participate in this event which has focused much needed attention to two critically important issues facing the stem cell / Regenerative Medicine industry: the need for increasing and improving strategic collaborations among the key stakeholders namely, development stage biotech companies, academic Institutions and government agencies, together with the attendant need to develop and recruit trained scientific personnel to meet both current and future industrial demands. Failure to address these issues rapidly and effectively within the U.S. risks the significant loss of intellectual property research and development and value to industrial sectors abroad."

The Stem Cell Partnering Series is a not-for-profit organization that actively supports the development and sustainability of the stem cell industry by fostering business collaborations and career development.

For more information on National Stem Cell Holding, Inc. please contact us at the company website: http://www.nationalstemcell.com or http://www.pinksheets.com.

About National Stem Cell Holding, Inc.

National Stem Cell Holding, Inc. is a hybrid biotechnology company focused on developing therapeutics based upon the use of human stem cells and their derivatives. The term 'hybrid' refers to both the business model as well its product line. The Company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These include but are not limited to: cancer, heart disease, diabetes, neurodegenerative diseases and auto immune conditions. In addition to its work with stem cell therapeutics, the Company is leveraging its commercial infrastructure and product development capabilities of its wholly-owned subsidiaries The Sperm Bank of NY (tissue Bank and IVF laboratory) and National Stem Cell Blood Laboratories Inc (cord blood banking program), and its affiliate, Decouverte Cosmetique, Inc. (cosmetics). The Company's investigational products are focused on the improvement of the quality of life for patients and their families. The Company's multi-facetted R&D program has demonstrated results with over 10 patent applications and multiple products ready to enter the market. The Company is headquartered in Mountainside, NJ and has facilities at multiple academic institutions.

"Safe Harbor Statement"

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact:

Michael Cohen

Phone: (212)792-6188

ir@nationalstemcell.com


'/>"/>
SOURCE National Stem Cell Holding, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. International Confocal Microscopy Working Group Established to Advance Practice of Reflective Confocal Microscopy
2. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
3. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
4. IBF Conferences Inc., (International Business Forum) and BioEnterprise Present the 2nd Annual Global Healthcare Investing Conference
5. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
6. National Fire Protection Association (NFPA) Sets New National Standard for CO Screening by Pulse CO-Oximetry(TM)
7. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
8. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
9. Siemens and National Jewish Medical and Research Center Form Strategic Alliance to Advance Shared Vision of Personalized Medicine
10. National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welchs Foods
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Inc. (NYSE: DPLO) announced today that its new website has gone live. On Thursday, Feb. 4, ... Visit the new site: www.diplomat.is ... ... ... "The goal was to reimagine the website and create a smarter, ...
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical industry ... a host of launch activities including the identification and ... launch activity is especially high in the oncology therapeutic ... Best Practices and the Role of Medical Affairs in ... focused on oncology therapies find better ways to utilize ...
(Date:2/4/2016)... New FDA action date of July 22, 2016   ... 22, 2016   --> - New FDA ... - Lifitegrast has the potential to be the only product approved ... and symptoms of dry eye disease in adults --> - ... the U.S. in the past decade indicated for the treatment of signs and ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
Breaking Biology Technology:
(Date:2/5/2016)... , Feb. 5, 2016 ... addition of the "Global Facial Recognition ... --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced ... Recognition Market 2016-2020" report to their ... ( http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition ...
(Date:2/3/2016)... 3, 2016 Vigilant Solutions announces today that ... Missouri solved two recent hit-and-run ... data from Vigilant Solutions. Brian Wenberg ... the victim was walking out of a convenience store and witnessed an elderly ... his vehicle, striking his vehicle and leaving the scene.  ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
Breaking Biology News(10 mins):